These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29213041)

  • 1. [Perampanel in the treatment of patients with epilepsy].
    Rider FK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):63-69. PubMed ID: 29213041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
    Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
    Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perampanel: Does it have broad-spectrum potential?
    Potschka H; Trinka E
    Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
    Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
    Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
    Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
    Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
    Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
    Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
    Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
    Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
    Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
    Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures.
    de Biase S; Gigli GL; Nilo A; Romano G; Valente M
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):93-102. PubMed ID: 30577702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy.
    Faulkner MA
    Drug Des Devel Ther; 2017; 11():2921-2930. PubMed ID: 29042752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perampanel: A Review in Drug-Resistant Epilepsy.
    Frampton JE
    Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of perampanel in epilepsy.
    Satlin A; Kramer LD; Laurenza A
    Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of perampanel in pediatric epilepsy.
    De Liso P; Moavero R; Coppola G; Curatolo P; Cusmai R; De Sarro G; Franzoni E; Vigevano F; Verrotti A
    Ital J Pediatr; 2017 Jun; 43(1):51. PubMed ID: 28577562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.
    Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E
    Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.